Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease

To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium‐glucose co‐transporters 1 and 2, in adults with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD3).

[1]  Shenyin Zhu,et al.  Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials. , 2022, Journal of diabetes and its complications.

[2]  M. Landray,et al.  Empagliflozin in Patients with Chronic Kidney Disease , 2022, The New England journal of medicine.

[3]  B. Perkins,et al.  Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition , 2022, Circulation.

[4]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[5]  P. Lapuerta,et al.  Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment , 2021, Diabetes, obesity & metabolism.

[6]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.

[7]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[8]  C. Cannon,et al.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.

[9]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[10]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[11]  S. Verma,et al.  Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors , 2020, JACC. Basic to translational science.

[12]  A. Levin,et al.  SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. , 2019, The lancet. Diabetes & endocrinology.

[13]  F. Geurts,et al.  The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. , 2019, Kidney international.

[14]  M. Jardine,et al.  Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis , 2019, Diabetes, obesity & metabolism.

[15]  Michael S. Kelly,et al.  Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease , 2018, Postgraduate medicine.

[16]  Merlin C Thomas,et al.  The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure , 2018, Diabetologia.

[17]  J. Buse,et al.  Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study , 2018, Diabetes, obesity & metabolism.

[18]  K. Khunti,et al.  The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies , 2016, Clinical pharmacology : advances and applications.

[19]  M. Woodward,et al.  Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. , 2014, The New England journal of medicine.

[20]  G. Bakris,et al.  Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy , 2014, American Journal of Nephrology.

[21]  A. Mithal,et al.  Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.

[22]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.